228 related articles for article (PubMed ID: 24040851)
1. One year long-term study on abuse liability of nalfurafine in hemodialysis patients.
Ueno Y; Mori A; Yanagita T
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):823-31. PubMed ID: 24040851
[TBL] [Abstract][Full Text] [Related]
2. Nalfurafine hydrochloride: a new drug for the treatment of uremic pruritus in hemodialysis patients.
Nakao K; Mochizuki H
Drugs Today (Barc); 2009 May; 45(5):323-9. PubMed ID: 19584962
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses.
Kamimura K; Yokoo T; Kamimura H; Sakamaki A; Abe S; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
PLoS One; 2017; 12(6):e0178991. PubMed ID: 28604788
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo pharmacological characterization of the main metabolites of nalfurafine hydrochloride.
Nakao K; Togashi Y; Honda T; Momen S; Umeuchi H; Sakakibara S; Tanaka T; Okano K; Mochizuki H
Eur J Pharmacol; 2012 Nov; 695(1-3):57-61. PubMed ID: 22981641
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological effects of nalfurafine hydrochloride, a kappa-opioid receptor agonist].
Nakao K; Hasebe K; Yoshikawa S; Ikeda K; Hirakata M; Miyamoto Y; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):185-91. PubMed ID: 21226314
[TBL] [Abstract][Full Text] [Related]
6. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.
Miyamoto Y; Oh T; Aihara E; Ando A
Handb Exp Pharmacol; 2022; 271():455-472. PubMed ID: 33201326
[TBL] [Abstract][Full Text] [Related]
7. Nalfurafine hydrochloride for the treatment of pruritus.
Inui S
Expert Opin Pharmacother; 2012 Jul; 13(10):1507-13. PubMed ID: 22663138
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Severity of Itching in Patients with End-Stage Renal Disease: Treatment with Nalfurafine Hydrochloride.
Nakamoto H; Kobayashi T; Noguchi T; Kusano T; Ashitani K; Imaeda H; Maezono M
Blood Purif; 2019; 47 Suppl 2():45-49. PubMed ID: 30943482
[TBL] [Abstract][Full Text] [Related]
9. International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Rayner HC; Larkina M; Wang M; Graham-Brown M; van der Veer SN; Ecder T; Hasegawa T; Kleophas W; Bieber BA; Tentori F; Robinson BM; Pisoni RL
Clin J Am Soc Nephrol; 2017 Dec; 12(12):2000-2007. PubMed ID: 28923831
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a novel ĸ-agonist for managing intractable pruritus in dialysis patients.
Kumagai H; Ebata T; Takamori K; Miyasato K; Muramatsu T; Nakamoto H; Kurihara M; Yanagita T; Suzuki H
Am J Nephrol; 2012; 36(2):175-83. PubMed ID: 22868684
[TBL] [Abstract][Full Text] [Related]
11. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
12. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies.
Wikström B; Gellert R; Ladefoged SD; Danda Y; Akai M; Ide K; Ogasawara M; Kawashima Y; Ueno K; Mori A; Ueno Y
J Am Soc Nephrol; 2005 Dec; 16(12):3742-7. PubMed ID: 16251241
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch) capsules 2.5 microg) , a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients].
Nakao K; Ando A; Hirakata M; Ando N; Takeshita K; Miyamoto Y; Mochizuki H
Nihon Yakurigaku Zasshi; 2010 May; 135(5):205-14. PubMed ID: 20467170
[No Abstract] [Full Text] [Related]
14. Nalfurafine hydrochloride, a selective κ opioid receptor agonist, has no reinforcing effect on intravenous self-administration in rhesus monkeys.
Nakao K; Hirakata M; Miyamoto Y; Kainoh M; Wakasa Y; Yanagita T
J Pharmacol Sci; 2016 Jan; 130(1):8-14. PubMed ID: 26786553
[TBL] [Abstract][Full Text] [Related]
15. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study.
Kumagai H; Ebata T; Takamori K; Muramatsu T; Nakamoto H; Suzuki H
Nephrol Dial Transplant; 2010 Apr; 25(4):1251-7. PubMed ID: 19926718
[TBL] [Abstract][Full Text] [Related]
16. Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
Yagi M; Tanaka A; Namisaki T; Takahashi A; Abe M; Honda A; Matsuzaki Y; Ohira H; Yoshiji H; Takikawa H;
J Gastroenterol; 2018 Oct; 53(10):1151-1158. PubMed ID: 29663077
[TBL] [Abstract][Full Text] [Related]
17. Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients.
Inui S; Shirakawa Y; Itami S
J Dermatol; 2012 Oct; 39(10):886-7. PubMed ID: 22142516
[No Abstract] [Full Text] [Related]
18. [Uremic pruritus: an unresolved challenge].
Aucella F; Gesuete A
G Ital Nefrol; 2009; 26(5):585-99. PubMed ID: 19802804
[TBL] [Abstract][Full Text] [Related]
19. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
Kawano T; Atsukawa M; Tsubota A; Shimada N; Toyoda H; Takaguchi K; Tani J; Morishita A; Hiraoka A; Mikami S; Ishikawa T; Okubo H; Watanabe T; Okubo T; Arai T; Hayama K; Itokawa N; Kondo C; Iwakiri K
Sci Rep; 2022 May; 12(1):7311. PubMed ID: 35508514
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch
Kozono H; Yoshitani H; Nakano R
Int J Nephrol Renovasc Dis; 2018; 11():9-24. PubMed ID: 29391822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
